ARTICLE | Company News
Halozyme Therapeutics Inc. (NASDAQ:HALO) raised its 2017 revenue guidance after announcing two separate licensing deals for its Enhanze drug-delivery technology with Bristol-Myers Squibb Co. (NYSE:BMY) and Roche (SIX:ROG; OTCQX:RHHBY).
The biotech now expects 2017 revenues to be in the range of $245-$260 million, up from previous guidance of $115-$130 million...